In the BioHarmony Drug Report Database
Botulinum toxin type a
Dysport, Nuceiva (botulinum toxin type a) is an unknown pharmaceutical. Botulinum toxin type a was first approved as Dysport on 2019-09-27. It is used to treat blepharospasm, dystonia, fissure in ano, genetic skin diseases, and muscle rigidity amongst others in the USA. It has been approved in Europe to treat skin aging.
Trade Name
|
Nuceiva |
|---|---|
Common Name
|
botulinum toxin type a |
ChEMBL ID
|
CHEMBL4297862 |
Indication
|
blepharospasm, dystonia, fissure in ano, genetic skin diseases, muscle rigidity, skin aging, strabismus |
Drug Class
|
Fluoroquinolone derivatives, nonantibacterial indications (e.g., antineoplastic antibiotics) |
Image (chem structure or protein)
